Improvements After 3-Year Ustekinumab or TNFi PsA Treatment Improvements After 3-Year Ustekinumab or TNFi PsA Treatment

Did these therapies lead to outcome and productivity improvements among psoriatic arthritis patients? A new study evaluated the real-world effects.Arthritis Research & Therapy
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news